NASDAQ · Biotechnology · USD

ADARx Pharmaceuticals, Inc. (ADRX) Stock Analysis

ADARx Pharmaceuticals, Inc. (ADRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ADRX

$17.13

−$0.55 (−3.11%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ADRX with… →

ADRX Key Statistics

As of Oct 21, 2026

Trading

Open: $17.58
Previous Close: $17.68
Day's Range: 17.00–18.17
52-Week Range: 16.61–23.21
Volume: 441.52K

Valuation

Market Cap: $1.83B
P/E Ratio: unprofitable
P/S ratio: 298.60
EPS (ttm): −1.16

Financials (FY)

Revenue (FY): $3.45M
Net Income (FY): −$73.09M
Shares Outstanding: 106.80M

Dividend and dates

Avg Volume: 882.97K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

ADARx Pharmaceuticals, Inc. (ADRX) has a market capitalization of $1.83B.

In fiscal 2025, ADRX reported revenue of $3.45M.

ADRX Revenue and Earnings by Fiscal Year

FY ends December

Fiscal year	Revenue	Net income	Net margin
2025	$3.45M	−$73.09M	−2,119.1%
2024	$0.00	−$46.36M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$3.45M	—	−$88.37M	−$73.09M	−2,119.1%
2024	$0.00	—	−$58.23M	−$46.36M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ADRX Valuation vs Biotechnology Median

Median of 608 stocks

Metric	ADRX	Biotechnology median	vs median
P/S ratio	298.60	13.30	22.5x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ADARx Pharmaceuticals, Inc. (ADRX) carries a market capitalisation of $1.83B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 100 employees.

ADRX last closed at $17.13 on October 21, 2026. That is −$0.55 (−3.11%) against the previous close. The 52-week range on file runs from $16.61 to $23.21. The latest close sits 3.13% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $3.45M. The same year closed with a net loss of $73.09M. Earnings per share on a trailing basis come to −1.16.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 298.6 times revenue. On price-to-sales that is 22.5 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Growth & Income

No dividend is on file for ADRX.

2026 is still running; the total return is −11.47% year to date.

Peer Comparison

ADARx Pharmaceuticals, Inc. (ADRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
ADARx Pharmaceuticals, Inc.	ADRX	$1.83B	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. ADARx Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About ADARx Pharmaceuticals, Inc.

ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer's disease. The company was incorporated in 2019 and is based in San Diego, California.

Visit website →